Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis
1995; Wiley; Volume: 38; Issue: 2 Linguagem: Inglês
10.1002/art.1780380202
ISSN1529-0131
AutoresWilliam P. Arend, Jean‐Michel Dayer,
Tópico(s)Systemic Lupus Erythematosus Research
ResumoArthritis & RheumatismVolume 38, Issue 2 p. 151-160 ReviewFree to Read Inhibition of the production and effects of interleukins-1 and tumor necrosis factor α in rheumatoid arthritis William P. Arend MD, Corresponding Author William P. Arend MD University of Colorado School of Medicine, DenverDivision of Rheumatology, Box B-115, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO, 80262Search for more papers by this authorJean-Michel Dayer MD, Jean-Michel Dayer MD Hǒpital Cantonal Universitaire, Geneva, SwitzerlandSearch for more papers by this author William P. Arend MD, Corresponding Author William P. Arend MD University of Colorado School of Medicine, DenverDivision of Rheumatology, Box B-115, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO, 80262Search for more papers by this authorJean-Michel Dayer MD, Jean-Michel Dayer MD Hǒpital Cantonal Universitaire, Geneva, SwitzerlandSearch for more papers by this author First published: February 1995 https://doi.org/10.1002/art.1780380202Citations: 685AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Arend WP, Dayer J-M: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33: 305– 315, 1990 2 Elliott MJ, Maini RN: New directions for biological therapy in rheumatoid arthritis. Int Arch Allergy Appl Immunol 104: 112– 125, 1994 3 Lacraz S, Isler P, Vey E, Welgus HG, Dayer J-M: Direct contact between T lymphocytes and monocytes is a major pathway for the induction of metalloproteinase expression. J Biol Chem 269: 22027– 22033, 1994 4 Hollander AP: Criteria for identifying mediators of tissue damage in human autoimmune diseases. Autoimmunity 9: 171– 176, 1991 5 Hollander AP, Atkins RM, Eastwood DM, Dieppe PA, Elson CJ: Human cartilage is degraded by rheumatoid arthritis synovial fluid but not by recombinant cytokines in vitro. Clin Exp Immunol 83: 52– 57, 1991 6 Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M: Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244– 247, 1989 7 Chandrasekhar S, Harvey AK, Hrubey PS, Bendele AM: Arthritis induced by interleukin-1 is dependent on the site and frequency of intraarticular injection. Clin Immunol Immunopathol 55: 382– 400, 1990 8 Staite ND, Richard KA, Aspar DG, Franz KA, Galinet LA, Dunn CJ: Induction of an acute erosive monarticular arthritis in mice by interleukin-1 and methylated bovine serum albumin. Arthritis Rheum 33: 253– 260, 1990 9 Van de Loo AAJ, Arntz OJ, van den Berg WB: Flare-up of experimental arthritis in mice with murine recombinant IL-1. Clin Exp Immunol 87: 196– 202, 1992 10 Hom JT, Cole H, Bendele AM: Interleukin-1 enhances the development of spontaneous arthritis in MRL/lpr mice. Clin Immunol Immunopathol 55: 109– 119, 1990 11 Hom JT, Cole H, Estridge T, Gliszczynski VL: Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant mice. Clin Immunol Immunopathol 62: 56– 65, 1992 12 van de Loo AAJ, van den Berg WB: Effects of murine recombinant interleukin-1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 49: 238– 245, 1990 13 Van Beuningen HM, Arntz OJ, van den Berg WB: In vivo effects of interleukin-1 on articular cartilage: prolongation of proteoglycan metabolic disturbances in old mice. Arthritis Rheum 34: 606– 615, 1991 14 O'Byrne EM, Blancuzzi V, Wilson DE, Wong M, Jeng AY: Elevated substance P and accelerated cartilage degradation in rabbit knees injected with interleukin-1 and tumor necrosis factor. Arthritis Rheum 33: 1023– 1028, 1990 15 McDonnell J, Hoerrner LA, Lark MW, Harper C, Dey T, Lobner J, Eiermann G, Kazazis D, Singer II, Moore VL: Recombinant human interleukin-1 β-induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid. Arthritis Rheum 35: 799– 805, 1992 16 Hasty KA, Reife RA, Kang AH, Stuart JM: The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 33: 388– 397, 1990 17 Hutchinson NI, Lark MW, MacNaul KL, Harper C, Hoerrner LA, McDonnell J, Donatelli S, Moore V, Bayne EK: In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin-1β. Arthritis Rheum 35: 1227– 1233, 1992 18 Case JP, Lafyatis R, Remmers EF, Kumkumian GK, Wilder RL: Transin/stromelysin expression in rheumatoid synovium. Am J Pathol 135: 1055– 1064, 1989 19 McCachren SS, Haynes BF, Niedel JE: Localization of collagenase mRNA in rheumatoid arthritis synovium by in situ hybridization histochemistry. J Clin Immunol 10: 19– 27, 1990 20 Firestein GS, Paine MM: Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol 140: 1309– 1314, 1992 21 Fons AF, van de Loo FA, Onno J, Arntz Otterness IG, van den Berg WB: Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin-1 antibodies in experimental arthritis. J Rheumatol 19: 348– 356, 1992 22 van den Berg WB, Joostens LAB, Helsen M, van de Loo FA: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95: 237– 243, 1994 23 Yodlowski ML, Hubbard JR, Kispert J, Keller K, Sledge CB, Steinberg JJ: Antibody to interleukin-1 inhibits the cartilage degradative and thymocyte proliferative actions of rheumatoid synovial culture medium. J Rheumatol 17: 1600– 1607, 1990 24 Arend WP: Interleukin-1 receptor antagonist. Adv Immunol 54: 167– 227, 1993 25 Arend WP, Welgus HG, Thompson RC, Eisenberg SP: Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 85: 1694– 1697, 1990 26 Seckinger P, Kaufmann M-T, Dayer J-M: An interleukin-1 inhibitor affects both cell-associated interleukin-1-induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells. Immunobiology 180: 316– 327, 1990 27 Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer J-M, Raisz LG: Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 145: 4181– 4184, 1990 28 Seckinger P, Yaron I, Meyer FA, Yaron M, Dayer J-M: Modulation of the effects of interleukin-1 on glycosaminoglycan synthesis by the urine-derived interleukin-1 inhibitor, but not by interleukin-6. Arthritis Rheum 33: 1807– 1814, 1990 29 Smith RJ, Chin JE, Sam LM, Justen JM: Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 34: 78– 83, 1991 30 Smith RJ, Justen JM, Ulrich RG, Lund JE, Sam LM: Induction of neutral proteinase and prostanoid production in bovine nasal chondrocytes by interleukin-1 and tumor necrosis factor α: modulation of these cellular responses by interleukin-6 and platelet-derived growth factor. Clin Immunol Immunopathol 64: 135– 144, 1992 31 Schwab JH, Anderle SK, Brown RR, Dalldorf FG, Thompson RC: Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 59: 4436– 4442, 1991 32 Matsukawa A, Ohkawara S, Maeda T, Takagi K, Yoshinaga M: Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits. Clin Exp Immunol 93: 206– 211, 1993 33 Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND: The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36: 1305– 1314, 1993 34 Henderson B, Thompson RC, Hardingham T, Lewthwaite J: Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 3: 246– 249, 1991 35 Lewthwaite J, Blake SM, Hardingham TE, Warden PJ, Henderson B: The effect of recombinant human interleukin-1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J Rheumatol 21: 467– 472, 1994 36 Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM: Suppression of monocyte function and differential regulation of IL-1 and IL-lra by IL-4 contribute to resolution of experimental arthritis. J Immunol 151: 4344– 4351, 1993 37 Barkley DEH, Feldmann M, Maini RN: Cells with dendritic morphology and bright interleukin-1 α staining circulate in the blood of patients with rheumatoid arthritis. Clin Exp Immunol 80: 25– 31, 1990 38 Goto M, Fujisawa M, Yamada A, Okabe T, Takaku F, Sasano M, Nishioka K: Spontaneous release of angiotensin converting enzyme and interleukin-1β from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann Rheum Dis 49: 172– 176, 1990 39 Zangerle PF, De Groote D, Lopez M, Meuleman RJ, Vrindts Y, Fauchet F, Dehart I, Jadoul M, Radoux D, Franchimont P: Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IFN γ and GM-CSF) in whole blood. II. Application to rheumatoid arthritis and osteoarthritis. Cytokine 4: 568– 575, 1992 40 Ruschen S, Stellberg W, Warnatz H: Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls. Clin Exp Immunol 89: 32– 37, 1992 41 Dularay B, Westacott CI, Elson CJ: IL-1 secreting cell assay and its application to cells from patients with rheumatoid arthritis. Br J Rheumatol 31: 19– 24, 1992 42 Holt I, Cooper RG, Denton J, Meager A, Hopkins SJ: Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol 31: 725– 733, 1992 43 Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawelee G: Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 51: 731– 734, 1992 44 Malyak M, Swaney RE, Arend WP: Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies: potential contribution from synovial fluid neutrophils. Arthritis Rheum 36: 781– 789, 1993 45 Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC: Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme disease. Lancet 341: 146– 148, 1993 46 Firestein GS, Alvaro-Garcia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144: 3347– 3353, 1990 47 Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN: Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 31: 653– 661, 1992 48 Wood NC, Dickens E, Symons JA, Duff GW: In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin Immunol Immunopathol 62: 295– 300, 1992 49 Yanni G, Whelan A, Feighery C, Quinlan W, Symons J, Duff G, Bresnihan B: Contrasting levels of in vitro cytokine production by rheumatoid synovial tissues demonstrating different patterns of mononuclear cell infiltration. Clin Exp Immunol 93: 387– 395, 1993 50 Farahat MN, Yanni G, Poston R, Panayi GS: Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 52: 870– 875, 1993 51 Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM, Yu C, Zvaifler NJ: IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 149: 1054– 1062, 1992 52 Koch AE, Kunkel SL, Chensue SW, Haines GK, Strieter RM: Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 65: 23– 29, 1992 53 Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maini RN: Localization of interleukin-1 α, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 31: 801– 809, 1992 54 Firestein GS, Boyle D, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, Arend WP: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 37: 644– 652, 1994 55 Danis VA, Kulesz AJ, Nelson DS, Brooks PM: The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis. Clin Exp Immunol 79: 335– 340, 1990 56 Chang D-M, Weinblatt ME, Schur PH: The effects of methotrexate on interleukin-1 in patients with rheumatoid arthritis. J Rheumatol 19: 1678– 1682, 1992 57 Meyer FA, Yaron I, Mashiah V, Yaron M: Methotrexate inhibits proliferation but not interleukin-1-stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 20: 238– 242, 1993 58 Thomas R, Carroll GJ: Reduction of leukocyte and interleukin-1 β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 36: 1244– 1252, 1993 59 Thornberry NA, Peterson EP, Zhao JJ, Howard AD, Griffin PR, Chapman KT: Inactivation of interleukin-1β converting enzyme by peptide (acyloxy)methyl ketones. Biochemistry 33: 3934– 3940, 1994 60 Symons JA, Eastgate JA, Duff GW: A soluble binding protein specific for interleukin-1β is produced by activated mononuclear cells. Cytokine 2: 190– 198, 1990 61 Symons JA, Eastgate JA, Duff GW: Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 174: 1251– 1254, 1991 62 Dreylow B, Capezio J, Lovis R, Jacobs C, Landay A, Pope RM: Phase I study of recombinant human interleukin-1 receptor administered intra-articularly in active rheumatoid arthritis (abstract). Arthritis Rheum 36 (Suppl 9): S39, 1993 63 Lebsack ME, Paul CC, Bloedow DC, Burch FX, Sack MA, Chase W, Catalano MA: Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis (abstract). Arthritis Rheum 34 (Suppl 9): S45, 1991 64 Lebsack ME, Paul CC, Martindale JJ, Catalano MA: A dose-and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis (abstract). Arthritis Rheum 36 (Suppl 9): S39, 1993 65 Evans C, Robbins PD: Prospects for treating arthritis by gene therapy. J Rheumatol 21: 779– 782, 1994 66 Roessler FJ, Allen ED, Wilson JM, Hartman JW, Davidson BL: Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 92: 1085– 1092, 1993 67 Hartman JW, Davidson BL, Roessler FJ: Genetic modification of synoviocytes in vivo using recombinant adenoviral vectors (abstract). Arthritis Rheum 36 (Suppl 9): S64, 1993 68 Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchaneek MK, Hung GHL, Glorioso JC, Robbins PD, Evans CH: Intraarticular expression of biologically active interleukin-1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 90: 10764– 10768, 1993 69 Brennan FM, Maini RN, Feldmann M: TNFα-a pivotal role in rheumatoid arthritis. Br J Rheumatol 31: 293– 298, 1992 70 Dayer J-M, Fenner H: The role of cytokines and their inhibitors in arthritis. Ballieres Clin Rheumatol 6: 485– 516, 1992 71 Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 21: 2575– 2579, 1991 72 Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA: Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 33: 542– 552, 1990 73 Zarco P, Maestre C, Herrero-Beaumont G, Gonzalez E, Garcia-Hoyo R, Navarro FJ, Braquet P, Egido J: Involvement of platelet-activating factor and tumor necrosis factor in the pathogenesis of joint inflammation in rabbits. Clin Exp Immunol 88: 318– 323, 1992 74 Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 10: 4025– 4031, 1991 75 Brahn E, Peacock DJ, Banquerigo ML, Liu DY: Effects of tumor necrosis alpha (TNF-α) on collagen arthritis. Lymphokine Cytokine Res 11: 253– 256, 1992 76 Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS: Acceleration of onset of collagen-induced arthritis by intraarticular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 898: 244– 250, 1992 77 Thorbecke G, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA: Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89: 7375– 7379, 1992 78 Piquet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77: 510– 514, 1992 79 Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89: 9784– 9788, 1992 80 Williams RO, Mason LJ, Feldmann M, Maini RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A 91: 2762– 2766, 1994 81 Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602– 6607, 1993 82 Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C: Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 49: 665– 667, 1990 83 Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilagepannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34: 1125– 1132, 1991 84 Deleuran BW, Chu C-Q, Field M, Brennan FM, Mitchell T, Feldmann M, Maini RN: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 35: 1170– 1178, 1992 85 Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M: Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 22: 1907– 1912, 1992 86 Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173: 699– 703, 1991 87 Van Leenan D, van der Poll T, Levi M, ten Cate H, van Deventer SJH, Hack CE, Aarden LA, ten Cate JW: Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 151: 2318– 2325, 1993 88 Parmely MJ, Zhou W-W, Edwards CK III, Borcherding DR, Silverstein R, Morrison DC: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J Immunol 151: 389– 396, 1993 89 Barrera P, Boerbooms AMT, Janssen EM, Sauerwein RW, Gallati H, Mulder J, de Boo T, Demacker PNM, van de Putte LBA, van der Meer JWM: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 36: 1070– 1079, 1993 90 Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35: 1160– 1169, 1992 91 Chikanza IC, Roux-Lombard P, Dayer J-M, Panayi GS: Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 92: 19– 22, 1993 92 Roux-Lombard P, Punzi L, Hasler F, Bas S, Todesco S, Gallati H, Guerne P-A, Dayer J-M: Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 36: 485– 489, 1993 93 Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175: 323– 329, 1992 94 Moreland LW, Margolies GR, Heck LW, Saway PA, Jacobs C, Beck C, Blosch C, Koopman WJ: Soluble tumor necrosis factor receptor: results of a phase I dose-escalation study in patients with rheumatoid arthritis (abstract). Arthritis Rheum 37 (Suppl 6): R27, 1994 95 Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36: 1681– 1690, 1993 96 Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen J, Leeb B, Breedveld EC, Macfarlane JD, Bijl JA, Woody JN: TNF α blockade in rheumatoid arthritis: results of a multicenter placebo-controlled, double-blind trial of chimeric anti-TNF α monoclonal antibody (cA2) in refractory disease (abstract). Arthritis Rheum 37 (Suppl 9): S283, 1994 97 Rankin ECC, Choy EHS, Kassimos D, Sopwith M, Kingsley G, Isenberg DA, Panayi GS: A double blind, placebocontrolled, ascending dose trial of the recombinant humanised anti-TNFα antibody CDP571 in patients with rheumatoid arthritis: a preliminary report (abstract). Arthritis Rheum 37 (Suppl 9): S295, 1994 98 Cope AP, Londei M, Chu NR, Cohen SBA, Elliott MJ, Brennan FM, Maini RN, Feldmann M: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94: 749– 760, 1994 99 Campion GV: The prospect for cytokine based therapeutic strategies in rheumatoid arthritis. Ann Rheum Dis 53: 485– 487, 1994 100 Van den Berg WS, Joosten LAB, Helsen MA, van Lent PLEM, van de Loo FAJ: Cytokine profile dependent on the type of arthritis: dominant role of IL-1 in cartilage destruction (abtract). Arthritis Rheum 37 (Suppl 9): S193, 1994 101 Russell D, Tucker K, Kohno H, Thompson RC, Schwab J: Inhibition of tumor necrosis factor is effective alone or in combination with inhibition of interleukin-1 in reducing joint swelling in rodent bacterial cell wall-induced arthritis (abstract). Arthritis Rheum 37 (Suppl 9): S279, 1994 Citing Literature Volume38, Issue2February 1995Pages 151-160 ReferencesRelatedInformation
Referência(s)